![Shigeyuki Nishinaka](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Shigeyuki Nishinaka
Directeur/Membre du Conseil chez
UROVANT SCIENCES LTD.
Profil
Shigeyuki Nishinaka is currently a Director at Sumitomo Pharma America, Inc., Meltin MMI KK, Myovant Sciences Ltd., Urovant Sciences, Inc., Urovant Sciences Ltd., and Sumitovant Biopharma, Inc. He is also a Managing Executive Officer at Sumitomo Pharma Co., Ltd. His former position was Director General-Inspection Bureau at Financial Services Agency.
He holds a doctorate degree from Hiroshima University.
Postes actifs de Shigeyuki Nishinaka
| Sociétés | Poste | Début |
|---|---|---|
| UROVANT SCIENCES LTD. | Directeur/Membre du Conseil | 27/12/2019 |
Meltin MMI KK
 Meltin MMI KK Medical SpecialtiesHealth Technology Engages in research and development & commercialization of medical devices, welfare equipment and robots for finger paralysis | Directeur/Membre du Conseil | - |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for oncology, CNS, urology and rare diseases | Directeur/Membre du Conseil | - |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company which develops and commercializes therapies for urologic conditions | Directeur/Membre du Conseil | 01/12/2019 |
Anciens postes connus de Shigeyuki Nishinaka
| Sociétés | Poste | Fin |
|---|---|---|
| MYOVANT SCIENCES LTD. | Directeur/Membre du Conseil | - |
Financial Services Agency
 Financial Services Agency General GovernmentGovernment Regulates and provides financial services | Corporate Officer/Principal | - |
Sumitovant Biopharma, Inc.
 Sumitovant Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets drugs | Directeur/Membre du Conseil | - |
| SUMITOMO PHARMA CO., LTD. | Directeur/Membre du Conseil | 25/06/2024 |
Formation de Shigeyuki Nishinaka
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
33
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Sumitomo Pharma Co., Ltd.
 Sumitomo Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical and other chemical products | Health Technology |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for oncology, CNS, urology and rare diseases | Health Technology |
Hiroshima University
 Hiroshima University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Financial Services Agency
Financial Services Agency General GovernmentGovernment Regulates and provides financial services | Government |
Meltin MMI KK
Meltin MMI KK Medical SpecialtiesHealth Technology Engages in research and development & commercialization of medical devices, welfare equipment and robots for finger paralysis | Health Technology |
Myovant Sciences Ltd.
 Myovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides women's health and prostate cancer solutions | Health Technology |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company which develops and commercializes therapies for urologic conditions | Health Technology |
Urovant Sciences Ltd.
 Urovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes therapies for urologic conditions | Health Technology |
Sumitovant Biopharma, Inc.
Sumitovant Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets drugs | Health Technology |
